Ken Griffin Pro Qr Therapeutics N.V. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$1.65 - $2.39 $56,430 - $81,738	-34,200 Reduced 95.0%	1,800 $2,000
Q1 2024 May 15, 2024	BUY	$1.89 - $2.85 $23,814 - $35,910	12,600 Added 53.85%	36,000 $82,000
Q4 2023 Feb 14, 2024	BUY	$1.15 - $2.21 $26,909 - $51,714	23,400 New	23,400 $46,000
Q2 2023 Aug 14, 2023	SELL	$1.62 - $2.32 $3,888 - $5,568	-2,400 Reduced 4.34%	52,900 $85,000
Q1 2023 May 15, 2023	BUY	$1.99 - $3.66 $72,038 - $132,492	36,200 Added 189.53%	55,300 $117,000
Q4 2022 Feb 14, 2023	SELL	$0.8 - $3.7 $1,600 - $7,400	-2,000 Reduced 9.48%	19,100 $70,000
Q3 2022 Nov 14, 2022	SELL	$0.74 - $0.89 $19,314 - $23,229	-26,100 Reduced 55.3%	21,100 $16,000

17.3M

26.2K

8.6K

Ticker PRQR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,362,096
Market Cap $257M
Description
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clin...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.